

## FIS NOW STOCKS INNOHEP® FOR TREATMENT OF DVT



Oncology Associates would like to remind you of its contract for **Innohep®** (tinzaparin sodium for injection) with Pharmion Corporation. Innohep® is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin®).

Innohep® is now available through FloridaInfusion Services. Contact FIS directly at **800-624-0152** to place an order.

**NDC#: 67211-342-08**  
20,000 IU/mL  
2mL vial

**NDC#: 67211-342-53**  
20,000 IU/mL  
10 x 2mL vial

Oncology Associates now presents the first member's contract for **Aloxi™** (palonosetron hydrochloride) from MGI PHARMA, Inc. The contract is effective **September 8, 2003**.

Aloxi™ is offered as an injection at a dose of 0.25 mg for:

- The prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly

## ARANESP® SINGLEJECT® PREFILLED SYRINGES NOW AVAILABLE TO OA MEMBERS

Oncology Associates is pleased to announce the addition of **Aranesp® SingleJect® Prefilled Syringes** to the Amgen contract, effective **July 28, 2003**. As an OA Member on the Amgen contract, you automatically qualify for this new savings benefit.

According to John Christopher, President, Oncology Associates, "The inclusion of a vital product like Aranesp® SingleJect® Prefilled Syringes to the

Amgen contract provides our members with more convenient treatment options for their patients. We value our relationship with Amgen and their ability to meet our members' clinical needs."

Thank you for your support of Oncology Associates and your participation on the Amgen contract. Please contact Oncology Associates at **888-732-7352** with any questions.

NDC #	PRODUCT NAME	DESCRIPTION	PACKAGE SIZE
55513-039-04 Prefilled Syringe	Aranesp® SingleJect® (200 mcg/mL), single-use syringe	60 mcg, 0.3 mL	4 syringes per pack; 10 packs per case
55513-041-04 Prefilled Syringe	Aranesp® SingleJect® (200 mcg/mL), single-use syringe	100 mcg, 0.5 mL	4 syringes per pack; 10 packs per case
55513-044-01 Prefilled Syringe	Aranesp® SingleJect® (500 mcg/mL), single-use syringe	200 mcg, 0.4 mL	1 syringe per pack; 4 packs per case
55513-046-01 Prefilled Syringe	Aranesp® SingleJect® (500 mcg/mL), single-use syringe	300 mcg, 0.6 mL	1 syringe per pack; 4 packs per case



## OA SIGNS AGREEMENT WITH MGI PHARMA, INC. FOR ALOXI™

emetogenic cancer chemotherapy.

- The prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

OA members will receive a special pricing structure as well as a tiered rebate paid every six months.

Stan Storer, Senior National Account Manager for MGI PHARMA states, "On behalf of MGI PHARMA, we could not be more excited and

optimistic about the future.

Aloxi™ (palonosetron), a new 5HT3 antagonist, is now available! Our sales organization is ready for the challenge. Understandably, we have a winning partnership between MGI and Oncology Associates. Oncology Associates continues to have its members' best interests in mind, and we are excited about their decision to place Aloxi™ on contract. The next twelve months, with the availability of Aloxi™ will offer healthcare professionals a new therapy to treat CINV."

NDC #	PRODUCT NAME	DESCRIPTION
58063-797-25	Aloxi™	0.25 mg/5ml vial 1 ct.

**1-888-732-7352**

[www.rcmed.com](http://www.rcmed.com)

**ONCOLOGY ASSOCIATES**  
Physician Network Services